Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) vs Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)

Breztri Aerosphere and Trelegy Ellipta are both maintenance inhalers used to manage chronic obstructive pulmonary disease (COPD), but they contain different combinations of medications. Breztri Aerosphere combines a corticosteroid (budesonide), a long-acting muscarinic antagonist (glycopyrrolate), and a long-acting beta2-adrenergic agonist (formoterol fumarate), which work together to reduce inflammation, relax airway muscles, and improve breathing. Trelegy Ellipta, on the other hand, contains a different corticosteroid (fluticasone furoate), a long-acting muscarinic antagonist (umeclidinium), and a long-acting beta2-adrenergic agonist (vilanterol), offering a similar therapeutic effect with a different formulation that may be preferred based on individual response, side effect profile, or specific recommendations from a healthcare provider.

Difference between Breztri Aerosphere and Trelegy Ellipta

Metric	Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate)	Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)
Generic name	Budesonide/glycopyrrolate/formoterol fumarate	Fluticasone furoate/umeclidinium/vilanterol
Indications	COPD, including chronic bronchitis and emphysema	COPD, asthma
Mechanism of action	Corticosteroid, anticholinergic, long-acting beta2-adrenergic agonist (LABA)	Corticosteroid, long-acting muscarinic antagonist (LAMA), long-acting beta2-adrenergic agonist (LABA)
Brand names	Breztri Aerosphere	Trelegy Ellipta
Administrative route	Inhalation	Inhalation
Side effects	Upper respiratory tract infection, pneumonia, back pain, oral candidiasis	Upper respiratory tract infection, headache, back pain, dysphonia
Contraindications	Hypersensitivity to ingredients, status asthmaticus, acute bronchospasm	Hypersensitivity to ingredients, acute bronchospasm, status asthmaticus
Drug class	Inhaled corticosteroid, anticholinergic, LABA	Inhaled corticosteroid, LAMA, LABA
Manufacturer	AstraZeneca	GlaxoSmithKline

Efficacy

Breztri Aerosphere in COPD Management

Breztri Aerosphere is a combination inhaler that contains budesonide, glycopyrrolate, and formoterol fumarate. It is specifically designed for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). Clinical trials have demonstrated the efficacy of Breztri Aerosphere in improving lung function, reducing exacerbations, and enhancing the quality of life for individuals with COPD. The triple combination therapy targets inflammation, reduces bronchospasm, and opens airways, which are crucial factors in the management of COPD symptoms.

Trelegy Ellipta's Role in COPD

Trelegy Ellipta is another triple-combination inhaler that contains fluticasone furoate, umeclidinium, and vilanterol. It is approved for the once-daily maintenance treatment of COPD, including chronic bronchitis and emphysema. Clinical studies have shown that Trelegy Ellipta improves lung function and reduces the rate of moderate to severe exacerbations. The inhaler's components work synergistically to decrease inflammation, relax the muscles around the airways, and improve airflow, which can significantly benefit COPD patients.

Comparative Efficacy in COPD Treatment

Both Breztri Aerosphere and Trelegy Ellipta have been shown to be effective in the management of COPD. However, direct head-to-head comparative studies are limited, making it challenging to determine superiority between the two treatments. The choice between these inhalers may depend on individual patient factors, including response to medication, preference for inhaler device, and potential side effects. Healthcare providers consider these factors along with the clinical evidence when recommending the most appropriate treatment option for their COPD patients.

Conclusion

In conclusion, Breztri Aerosphere and Trelegy Ellipta have both been proven to be effective for the maintenance treatment of COPD. They offer different combinations of active ingredients but share the common goal of managing COPD symptoms, preventing exacerbations, and improving overall lung function. While more research may be needed to fully compare their efficacy, current evidence supports their use as valuable options in the COPD treatment arsenal. Patients should consult with their healthcare providers to determine which medication is best suited to their specific needs.

Regulatory Agency Approvals

Breztri Aerosphere

Food and Drug Administration (FDA), USA
Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Trelegy Ellipta

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Access Breztri Aerosphere or Trelegy Ellipta today

If Breztri Aerosphere or Trelegy Ellipta are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Breztri Aerosphere

Buy Trelegy Ellipta

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: